Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2012 December;60(6) > Minerva Cardioangiologica 2012 December;60(6):611-28





A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752




Minerva Cardioangiologica 2012 December;60(6):611-28

language: English

Dual antiplatelet therapy for primary and secondary prevention

Mathur A. P., Waller A. H., Dhruvakumar S., Mazza V., Gerula C., Maher J., Klapholz M., Kaluski E.

Division of Cardiology, Department of Medicine, University Hospital and New Jersey Medical School, Newark, NJ, USA


The concomitant use of aspirin and an ADP receptor (P2Y12) blocker, also known as dual antiplatelet therapy (DAPT), has been extensively investigated as a primary and secondary prevention strategy in an effort to reduce the risk of cardiovascular events. In this manuscript the authors review the current guideline recommendations for DAPT and discuss the scientific data that supports these recommendations. Reported are also the scientific knowledge gaps and how future studies are likely to delineate these issues. Incremental knowledge is not likely to be an alternative to individualized care provided by the astute clinician to his patient. In consideration for prescribing DAPT (drug, dosage and duration) the clinician will have to weigh the potential benefits (reduction in death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke) and risks (severe or life-threatening bleeding) for each and every patient.

top of page

Publication History

Cite this article as

Corresponding author e-mail